Introduction
Measuring the burden of malaria is challenging as the clinical features of the infection are non-specific and mimicked by many other infectious diseases and many deaths from malaria occur at home without prior investigation. However, there is a consensus that during the past 15 years both the number of cases of malaria and the number deaths from malaria has fallen by about a half, despite a substantial increase in the population of malaria endemic areas during this period. 1 This success has been achieved primarily through scaling up of [range 235-639] thousand preventable deaths from malaria, a large majority of the latter occurring in African children. 1 Further reductions in the malaria burden could be achieved through scaling up of currently employed control tools, especially in areas where coverage remains low, and this is a priority. However, in areas where good coverage has been achieved already, this is likely to become increasingly difficult and expensive as it will be necessary to reach populations that are difficult to access and to persuade those resistant to control measures, such as the use of ITNs, to adopt them. Furthermore, both the efficacy of ITNs and of ACTs are threatened by the emergence and spread of resistance to pyrethroid insecticides
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in Africa 3 and of artemisinin resistance in southeast Asia. 4 Thus, new control tools are needed as an additional measure in areas where current control methods, correctly applied, are not achieving full control of the infection, to replace the insecticides and drugs currently in use if resistance renders them ineffective and finally to contribute to elimination of the infection. Some of the control tools not widely in use that are currently available, or may become so in the near to medium term future, are shown in Table 1 .
Deciding on the optimal use of additional malaria control tools Development of ACTs was an enormous advance because, at the time that they were introduced, they were highly effective against blood stage infections of all five human malaria parasite species across the malaria endemic world and there was no known resistance.
Similarly, when first introduced, ITNs were highly effective in nearly all highly malaria endemic areas where the vector mosquitoes feed predominantly at night. Consequently, at this time, national policies for malaria control could be developed which were simple to follow and could be implemented across a country without a need to take into account regional differences in the epidemiology of the infection. This situation no longer applies in many countries so that the additional methods of malaria control becoming available will need to be deployed in a more focused manner to achieve their maximum impact, taking into account a number of variables such as the seasonality of malaria, its intensity and preferences of the population for specific control measures in different parts of a country. Two recent examples of how a rational, focused approach to the deployment of two new malaria control interventions has been developed or is being considered are described in the following two sections of the paper.
Seasonal malaria chemoprevention
In many parts of sub-Saharan Africa, malaria transmission is highly seasonal (Figure 1 ).
There are few data on the incidence of clinical episodes of malaria by month of year in subSaharan Africa but using monthly rainfall as a surrogate for malaria transmission allowed production of a map of the areas where malaria transmission is likely to be highly seasonal. 
The RTS,S/AS01 malaria vaccine
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Development of the RTS,S/AS01 malaria vaccine, the first malaria vaccine to obtain approval from a major regulatory authority (the European Medicines Agency) has taken 30 years.
Results from a large phase 3 trial conducted in 11 centres in 7 countries in sub-Saharan Africa showed that three doses of vaccine given to children aged 5-17 months followed by a booster dose 18 months later gave an efficacy of 36% against clinical attacks of malaria during a four year period of follow-up. 8 The vaccine was less effective when given with routine Expanded Programme of Immunisation (EPI) vaccine at the ages of 6-14 weeks. 8 An unexplained increase in meningitis was observed in older, but not in younger children who received the vaccine and there was a suggestion that the proportion of cases of severe malaria due to cerebral malaria was increased, although the overall incidence of severe malaria was reduced in vaccinated children. For these reasons, and because of concerns about the practicability of giving a fourth dose, WHO's SAGE committee did not recommend immediate deployment of the vaccine on a large scale but the conduct of 3-5 large scale pilot implementation studies. 9 Funding to support three large pilot studies has now been obtained and these are being planned. Where the vaccine might be be most effective if the results of the pilot studies suggest that it should be deployed more generally requires careful consideration.
The efficacy of RTS,S/AS01 in preventing clinical malaria showed some variation between study sites but the vaccine was effective across all sites, independent of the level of malaria transmission at that site. This was an important finding because the potential public health importance of the vaccine depends not only upon its efficacy but primarily upon the number of cases of malaria it would prevent in a particular epidemiological situation, and hence the potential financial savings to the health system that might follow from its deployment.
Analysis of the results of the phase 3 trial by site showed that at Kilifi, Kenya, the site with which intensity of infection will be the major factor in determining where it could be deployed most effectively.
Implications of a focused approach to malaria control
The need for more flexible control programmes has important consequences for national malaria control programmes. National scale-up of ITNs and ACTs requires predominantly experienced logisticians and not scientists. However, the design, implementation and monitoring of more complex programmes based on considerations of local epidemiological, sociological and economic factors requires staff well trained in a variety of disciplines including epidemiology, entomology, parasitology, social sciences and economics. Careful monitoring of new programmes will be essential so that they can be modified rapidly in the face of changes in the epidemiology of the infection brought about by the success of the intervention or by other factors, for example a change in the peak age of cases from young to school-aged children. 10 This will require a well-trained team of scientists. Thus, paradoxically, as malaria control improves and the malaria burden declines, more rather less well trained staff in areas such as entomology will be needed. Achieving the funds to needed to sustain these experienced teams at a time when the burden of malaria is decreasing will be challenging but is essential if the gains made are to be sustained and malaria to be eliminated. There are robust data from Ethiopia showing that mass drug administration of azithromycin for control of trachoma significantly reduced overall child mortality. Thus, it might be expected that giving azithromycin (which is also a weak antimalarial) as part of SMC might have a similar effect. This trial is investigating this. 
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